Skip to main content
. 2022 Aug 6;16:11795549221110501. doi: 10.1177/11795549221110501

Figure 2.

Figure 2.

Efficacy of Vigil in combination with durvalumab. (A) PFS of all study subjects, (B) OS of all study subjects, (C) PFS of TNBC subjects, (D) OS of TNBC subjects, (E) PFS of OC subjects, (F) OS of OC subjects.

OC indicates ovarian cancer; OS, overall survival; PFS, progression-free survival; TNBC, triple-negative breast cancer.